$9.00
Value $100M
BDSX and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$9.00
Value $100M
$1,431.67
Value $1.35T
Biodesix (BDSX) has a market value of $100M and Eli Lilly and Company (LLY) $1.35T. Over the last year, with dividends, BDSX moved +12.5% and LLY +40.5%. Dividend yield: BDSX none, LLY 0.44%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
BDSX$100M
LLY$1.35T
LLY is 13,533 times BDSX
Revenue, 12 months
BDSX$105M
LLY$86.5B
LLY is 822 times BDSX
Net income, 12 months
BDSX-$27M
LLY$27.6B
Operating margin
BDSX-18.7%
LLY–
ROIC
BDSX-28.5%
LLY35.5%
64.0 points apart
P/E
BDSX–
LLY49.0
Dividend yield
BDSX0.0%
LLY0.4%
0.4 points apart
5-year return
BDSX-94.1%
LLY+478.4%
572.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
BDSX-94.2%
LLY+478.4%
| Period | BDSXWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +12.5%Price +12.5% | +40.5%Price +39.6% |
| 3 years since November 16, 2023 | -68.3%-31.8% a yearPrice -68.3% | +148.1%+35.4% a yearPrice +143.2% |
| 5 years since November 15, 2021 | -94.1%-43.3% a yearPrice -94.1% | +478.4%+42.1% a yearPrice +454.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
BDSXBiodesixLLYEli Lilly and Company
| Price | $9.00 | $1,431.67 |
|---|---|---|
| Market value | $100M | $1.35T |
| Enterprise value (EV) | – | $1.40T |
| P/E | – | 49.0 |
| P/E, 5-year median | – | 49.9 |
| P/B | 11.5 | 33.5 |
| EV/EBIT | – | 40.1 |
| Free cash flow yield | – | 1.5% |
| Revenue, 12 months | $105M | $86.5B |
|---|---|---|
| Net income, 12 months | -$27M | $27.6B |
| Free cash flow, 12 months | -$19M | $19.7B |
| Earnings per share, 12 months | -$2.70 | $30.81 |
| Revenue growth, year on year | 24.1% | 44.7% |
| Revenue growth a year, past | +14.2%over 5 years | +21.6%over 5 years |
| EPS growth a year, past | – | +27.6%over 5 years |
| Gross margin | – | 83.6% |
|---|---|---|
| Operating margin | -18.7% | – |
| Net margin | -25.7% | 31.9% |
| ROIC | -28.5% | 35.5% |
| ROE | -594.8% | 88.6% |
| Cash | $28M | $4.9B |
|---|---|---|
| Total debt | – | $49.5B |
| Net debt / EBITDA | – | 1.2 |
| Interest cover | -2.5× | 38.9× |
| Dividend yield | – | 0.4% |
|---|---|---|
| Dividend per share, 12 months | – | $6.34 |
| Dividend growth a year, past | – | +15.2%over 5 years |
| Buyback yield | – | 0.3% |
| Shareholder yield | – | 0.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.35T) is about 13,533.3 times Biodesix ($100M), at today's prices.
Since November 15, 2021, BDSX's price moved -94.1% and LLY's +454.0%. With dividends: BDSX -94.1% (-43.3% a year), LLY +478.4% (+42.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Biodesix and 0.44% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.
Over the last twelve months, the net margin was -25.7% for Biodesix and 31.9% for Eli Lilly and Company, and the operating margin -18.7% and –. Revenue was $105M and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.